PathogenDx, Inc., the Arizona based technology company which provides a DNA-based pathogen testing platform for the cannabis, hemp, agriculture and food safety industries announced today that they have entered into a strategic partnership with Nationwide Laboratory Services/The Hayes Division, a national medical lab testing company based in Florida, to deploy PathogenDx’s proprietary microarray technology for rapid strain identification in the dermatological and podiatric fungal testing industry. As part of the terms of the agreement, Nationwide Laboratory Services will create a Laboratory Developed Test (LDT) based on PathogenDx’s testing technology. PathogenDx will serve as the Research & Development platform and Nationwide Labs will serve as the validator and launchpad for the services.
In making the announcement, CEO and Co-Founder Milan Patel said, “PathogenDx’s agreement with Nationwide Laboratory Services will offer doctors, patients and insurers ultra-rapid and less expensive fungal testing results in 6 hours or less, versus the industry standard of 72+ hours or more. We all know that DNA-based tests are far more rapid and accurate than plating cultures, but what PathogenDx uniquely offers is multiple pathogen testing as one multiplex test in 6 hours or less. We have already developed analogous testing for the fungal species needed in the microbial testing market in our other industry verticals. What this partnership with Nationwide Labs will allow us to do is to take that knowledge and expand into the medical testing market. A breakthrough moment for our multi-patented technology, this partnership allows us to move into the multi-billion dollar medical microbial testing market. This is a very exciting announcement for us.”